CiToxLAB expands inhalation test capabilities in North America and Europe
Opens rodent and non-rodent facility in Canada and will double rodent capacity in Hungary
CiToxLAB, a CRO working in non-clinical research, has increased its inhalation test capabilities in North America and Europe.
CiToxLAB-North America has opened a state-of-the-art rodent and non-rodent inhalation facility, adding the ability to evaluate pharmaceuticals, biological compounds and inhalation devices. For pharmaceutical companies inhalation tests are required for a range of drugs including those intended to treat allergy, asthma or COPD patients. For chemical companies there is a need to test the consequences of inhaling chemical products, especially within the REACH (Registration, Evaluation and Authorisation of Chemicals) programme.
The studies conducted in CiToxLAB-North America will use seven rodent suites and five non-rodent suites, with the facility able to perform studies by the inhalation route in all species, including NHPs. The firm says this will enable the group to conduct work not currently performed in Europe.
The Canadian team at CiToxLAB-North America has experience in exposure of multiple animal species to single or repeated nose-only and oronasal exposure routes in liquids, powders, vapours and metered dose inhalers.
CiToxLAB is currently doubling its rodent capacity in Europe at CiToxLAB Hungary in response to increased demand.
CiToxLAB-Hungary is equipped with three rodent suites and one non-rodent suite and the new area will be fully operational by the end of the second quarter.
This site has carried out more than 200 GLP inhalation studies in the last five years and has been conducting inhalation studies since 2000. Veterinary pathologists qualified to DVM level and experienced in inhalation studies support the inhalation teams in both regions.
The sites also offer a full range of support services including analytical capabilities. In addition CiToxLAB-North America has an on-site bioanalytical team working alongside the inhalation staff.
The services offered via the inhalation route in the Hungarian and North American facilities complement the expertise provided by the Group’s other facilities, including CiToxLAB-France and CiToxLAB-Scantox in Denmark.
CiToxLAB was created through last year’s merger of CIT and LAB Research and provides a comprehensive range of pre-clinical and specialist services.
